Dalcetrapib

CAS No. 211513-37-0

Dalcetrapib( JTT-705 | JTT705 | JTT 705 | RO-4607381 )

Catalog No. M17429 CAS No. 211513-37-0

Dalcetrapib, a rhCETP inhibitor (IC50=0.2 μM), increases the plasma HDL cholesterol.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 33 In Stock
5MG 51 In Stock
10MG 65 In Stock
25MG 122 In Stock
50MG 190 In Stock
100MG 332 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Dalcetrapib
  • Note
    Research use only, not for human use.
  • Brief Description
    Dalcetrapib, a rhCETP inhibitor (IC50=0.2 μM), increases the plasma HDL cholesterol.
  • Description
    Dalcetrapib, aslo known as JTT-705, is a CETP inhibitor. The drug was aimed at raising the blood levels of "good cholesterol" (cholesterol carried in HDL particles, aka HDL-C). Prevailing observations indicate that high HDL levels correlate with better overall cardiovascular health, though it remains unclear whether raising HDL levels consequently leads to an increase in cardiovascular health. Development of this drug was halted on May 7, 2012 “due to a lack of clinically meaningful efficacy.(In Vitro):Dalcetrapib (JTT-705) (0.1-10 μM; 21 h) dose-dependently increases pre-β-HDL formation.Dalcetrapib (0-30 μM; 24 h) inhibits the CETP activity of media in HepG2 in a dose-dependent manner.(In Vivo):Dalcetrapib (JTT-705) (30 or 100 mg/kg; p.o.; once a day for 3 days) increases plasma HDL cholesterol in rabbits.Dalcetrapib (100 mg/kg; i.g.; twice daily for 7 days) significantly increases fecal elimination of neutral sterols, bile acids, and plasma HDL-cholesterol.
  • In Vitro
    Dalcetrapib (JTT-705) (0.1-10 μM; 21 h) dose-dependently increases pre-β-HDL formation.Dalcetrapib (0-30 μM; 24 h) inhibits the CETP activity of media in HepG2 in a dose-dependent manner.
  • In Vivo
    Dalcetrapib (JTT-705) (30 or 100 mg/kg; p.o.; once a day for 3 days) increases plasma HDL cholesterol in rabbits.Dalcetrapib (100 mg/kg; i.g.; twice daily for 7 days) significantly increases fecal elimination of neutral sterols, bile acids, and plasma HDL-cholesterol. Animal Model:Male JW rabbits Dosage:30 or 100 mg/kg Administration:Oral administration, once a day for 3 days Result:Increased plasma HDL cholesterol by 27% and 54% at 30 mg/kg and 100 mg/kg, respectively.
  • Synonyms
    JTT-705 | JTT705 | JTT 705 | RO-4607381
  • Pathway
    Angiogenesis
  • Target
    FGFR
  • Recptor
    rhCETP
  • Research Area
    Cardiovascular Disease|Metabolic Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    211513-37-0
  • Formula Weight
    389.59
  • Molecular Formula
    C23H35NO2S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 50 mg/mL. 128.34 mM; H2O : < 0.1 mg/mL
  • SMILES
    c1(ccccc1NC(=O)C1(CC(CC)CC)CCCCC1)SC(=O)C(C)C
  • Chemical Name
    S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Niesor EJ, et al. J Lipid Res. 2010, 51(12), 3443-3454.
molnova catalog
related products
  • SU4984

    SU4984 is a cell-permeable, ATP-competitive and reversible inhibitor of the fibroblast growth factor receptor 1 (FGFR1).

  • SKLB 610

    SKLB610, a novel multi-targeted inhibitor, inhibits angiogenesis-related tyrosine kinase VEGFR2, FGFR2 and PDGFR.

  • Sucralfate

    Sucralfate is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.